RecoMed☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

RecoMed is one of 2138 Healthtech companies tracked from Africa. By capital raised it ranks in the long tail (ahead of 17% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

SA e-health startup RecoMed secures $324k investment 0 By Tom Jackson on November 23, 2017 News , Southern Africa South African e-health startup RecoMed has raised ZAR4.5 million (US$324,000) in funding to fund a shift to increasing product traction and market its products and services. RecoMed is an online healthcare marketplace, enabling consumers to easily book appointments with a diverse group of healthcare providers 24/7, who in turn benefit from increased patient traffic and practice efficiencies.

SA e-health startup RecoMed secures $324k investment 0 By Tom Jackson on November 23, 2017 News , Southern Africa South African e-health startup RecoMed has raised ZAR4.5 million (US$324,000) in funding to fund a shift to increasing product traction and market its products and services. RecoMed is an online healthcare marketplace, enabling consumers to easily book appointments with a diverse group of healthcare providers 24/7, who in turn benefit from increased patient traffic and practice efficiencies.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 17% of sector peers (real $). Modeled value above 34% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #71 of 113.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Pre-Seed$324K2017-11-23
   • First recorded raise — entered as Pre-Seed.
   • 3 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

RecoMed is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Public records name issuer insiders, not the funds in a round — these investor links come from corroborating sources.

See where RecoMed sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at RecoMed, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.